

Anti-TAFI/CPB2 Picoband Antibody
Catalog # ABO12682**Specification**

Anti-TAFI/CPB2 Picoband Antibody - Product Information

Application	WB, IHC-P, E
Primary Accession	Q96IY4
Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Format	Lyophilized

Description

Rabbit IgG polyclonal antibody for Carboxypeptidase B2(CPB2) detection. Tested with WB, IHC-P, ELISA in Human.

Reconstitution

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Anti-TAFI/CPB2 Picoband Antibody - Additional Information

Gene ID 1361

Other Names

Carboxypeptidase B2, 3.4.17.20, Carboxypeptidase U, CPU, Plasma carboxypeptidase B, pCPB, Thrombin-activable fibrinolysis inhibitor, TAFI, CPB2

Calculated MW

48424 MW KDa

Application Details

Immunohistochemistry(Paraffin-embedded Section), 0.5-1 µg/ml, Human, By Heat

ELISA , 0.1-0.5 µg/ml, Human, -
Western blot, 0.1-0.5 µg/ml, Human

Subcellular Localization

Secreted.

Tissue Specificity

Plasma; synthesized in the liver.

Protein Name

Carboxypeptidase B2

Contents

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na₂HPO₄, 0.05mg NaN₃.

Immunogen

E. coli-derived human CPB2 recombinant protein (Position: K166-D388). Human CPB2 shares 86.1% and 85.7% amino acid (aa) sequence identity with mouse and rat CPB2, respectively.

Purification

Immunogen affinity purified.

Cross Reactivity

No cross reactivity with other proteins

Storage

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time. Avoid repeated freezing and thawing.

Anti-TAFI/CPB2 Picoband Antibody - Protein Information

Name CPB2

Function

Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.

Cellular Location

Secreted.


Tissue Location


Plasma; synthesized in the liver.

Anti-TAFI/CPB2 Picoband Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-TAFI/CPB2 Picoband Antibody - Images



Western blot analysis of CPB2 expression in human placenta extract (lane 1) and HEPG2 whole cell lysates (lane 2). CPB2 at 48KD, 60KD was detected using rabbit anti- CPB2 Antigen Affinity purified polyclonal antibody (Catalog # ABO12682) at 0.5 µg/mL. The blot was developed using chemiluminescence (ECL) method .



CPB2 was detected in paraffin-embedded sections of human lung cancer tissues using rabbit anti-CPB2 Antigen Affinity purified polyclonal antibody (Catalog # ABO12682) at 1 µg/mL. The immunohistochemical section was developed using SABC method .

Anti-TAFI/CPB2 Picoband Antibody - Background

Carboxypeptidase B2 (CPB2), also known as carboxypeptidase U (CPU), plasma carboxypeptidase B (pCPB) or thrombin-activatable fibrinolysis inhibitor (TAFI), is an enzyme that, in humans, is encoded by the gene CPB2. CPB2 is synthesized by the liver and circulates in the plasma as a plasminogen-bound zymogen. When it is activated by proteolysis at residue Arg92 by the thrombin/thrombomodulin complex, CPB2 exhibits carboxypeptidase activity. Activated CPB2 reduces fibrinolysis by removing the fibrin C-terminal residues that are important for the binding and activation of plasminogen.